Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov;32 Suppl 2(Suppl 2):S211-6.
doi: 10.2337/dc09-S313.

Telemedical artificial pancreas: PARIS (Pancreas Artificial Telemedico Inteligente) research project

Alberto de Leiva  1 , María Elena Hernando; EDUAB-HSP; GBT-UPM; M Rigla, I Capel, E Brugués, B Pons, L Erdozain, A Prados, R Corcoy, E J Gómez, G García-Sáez, I Martínez-Sarriegui, A Rodríguez-Herrero, C Pérez-Gandía, F del Pozo
Affiliations

Telemedical artificial pancreas: PARIS (Pancreas Artificial Telemedico Inteligente) research project

Alberto de Leiva et al. Diabetes Care. 2009 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
PARIS Research Project. TAP integrates an SA based on a handheld personal digital assistant (PDA) to provide patients with closed-loop control strategies (personal and remote loop), based on real-time CGM, CSII (insulin pump), and a mobile GPRS-based telecommunication. The patient decides on the changes in the insulin pump programming, using the information coming from a glucose sensor. The physician suggests changes in the insulin program, using the information provided by the CGM and from the CSII, coming from the personal smart assistant (PSA) through the TMCS. Close-loop algorithms implemented in the PSA provide a real-time control of the insulin pump based on glucose sensor data.
Figure 2
Figure 2
PARIS clinical study 1. The main objective of the study was to evaluate clinical utilities of the telemedicine system (DIABTel) that includes an SA (iPAQ), provided with wireless communication facilities. In the control phase, type 1 diabetic patients directly submitted blood glucose levels from a conventional glucose monitor (Accuchek, Acculink modem) and insulin data to the diabetes center without any feedback. In the experimental phase, patients were assisted by telemedicine (DiabTel) System.
Figure 3
Figure 3
PARIS clinical study 2. The study evaluated the clinical impact of the combined use of real-time CGM (Guardian RT) together with telemedicine in insulin pump–treated (DTRON plus) type 1 diabetic subjects, integrated in the TAP. Insulin data were retrieved directly from the DTRON, plus insulin pump real-time CGM was used 3 days per week during the experimental phase. SMBG was used at all other times during both control and experimental phases. Data were available on the web and the patient's SA (iPAQ), which communicated with the DiabTel server.
See this image and copyright information in PMC

References

    1. Hovorka R: Continuous glucose monitoring and closed-loop systems. Diabet Med 2005; 23: 1– 12 - PubMed
    1. Baquette BV: A critical assessment of algorithms and challenges in the development of a close-loop artificial pancreas. Diabetes Technol Ther 2005; 7: 28– 47 - PubMed
    1. Owens C, Zisser H, Jovanovic L, Srinivasan B, Bonvin D, Doyle J, III: Run-to-run control of blood glucose concentration for people with type 1 diabetes mellitus. IEEE Trans Inf Technol Biomed 2006; 6: 996– 1005 - PubMed
    1. Hovorka R, Chassin LJ, Wilinska ME, Canonico V, Akwi JA, Federici MO, Massi-Benedetti M, Hutzli I, Zaugg C: Closing the loop: the Adicol experience. Diabetes Technol Ther 2004; 6: 307– 318 - PubMed
    1. Bailey TS, Zisser HC, Garg SK: Reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther 2007; 9: 203– 210 - PubMed

Publication types